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The extracellular matrix (ECM) is a critical regulator of neural network development
and plasticity. As neuronal circuits develop, the ECM stabilizes synaptic contacts,
while its cleavage has both permissive and active roles in the regulation of plasticity.
Matrix metalloproteinase 9 (MMP-9) is a member of a large family of zinc-dependent
endopeptidases that can cleave ECM and several cell surface receptors allowing for
synaptic and circuit level reorganization. It is becoming increasingly clear that the
regulated activity of MMP-9 is critical for central nervous system (CNS) development. In
particular, MMP-9 has a role in the development of sensory circuits during early postnatal
periods, called ‘critical periods.’ MMP-9 can regulate sensory-mediated, local circuit
reorganization through its ability to control synaptogenesis, axonal pathfinding and
myelination. Although activity-dependent activation of MMP-9 at specific synapses plays
an important role in multiple plasticity mechanisms throughout the CNS, misregulated
activation of the enzyme is implicated in a number of neurodegenerative disorders,
including traumatic brain injury, multiple sclerosis, and Alzheimer’s disease. Growing
evidence also suggests a role for MMP-9 in the pathophysiology of neurodevelopmental
disorders including Fragile X Syndrome. This review outlines the various actions of
MMP-9 during postnatal brain development, critical for future studies exploring novel
therapeutic strategies for neurodevelopmental disorders.
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Introduction
The capacity of the CNS of an animal to adapt to changing internal and external environments must
be oﬀset by the capacity to maintain network stability following changes. This stability-plasticity
balance is highly regulated and is necessary for adaptation and survival throughout the lifespan
of an organism. An important challenge in neuroscience remains to identify the mechanisms
Abbreviations: CNS, central nervous system; CPP, critical period plasticity; CRMP-2, collapsin response mediator protein-
2; DG, dentate gyrus; ECM, extracellular matrix; EGL, external granular layer; e-LTP, early-phase long term potentiation;
FXS, Fragile X syndrome; Fmr 1, Fragile X mental retardation gene 1; FMRP, Fragile X mental retardation protein; ICAM-5,
intercellular adhesion molecule-5; IGF-1, insulin growth factor – 1 (IGF-1); IGBP-6, insulin growth factor binding protein –
6; IGL, internal granular layer; L1CAM, L1 cell adhesion molecule; l-LTP, late-phase long term potentiation; MAPK,
mitogen-activated protein kinase; MMP-9, matrix metalloproteinase-9; NF155, neurofascin; NLG-1, neuroligin-1; OL,
oligodendrocytes; PKC, protein kinase C; PNN, perineuronal net; RGD, arginine-glycine-aspartate; SC, superior colliculus;
TIMP-1, tissue inhibitor of metalloproteinase-1.
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that regulate the dynamics between stability and plasticity. With
some 86–100 billion neurons and an approximately equal or
larger number of glial cells, depending upon the brain region
(Azevedo et al., 2009), the study of the brain has been likened to
the quest for understanding the universe, with multiple cellular
and molecular interactions that account for brain plasticity. Yet
many key mechanisms underlying synaptic plasticity are found
not in these brain cells themselves but in their interactions with
molecules in the extracellular space surrounding them (reviewed
by Ruoslahti, 1996a,b; Nicholson and Sykova, 1998; Shi and
Ethell, 2006; Šišková et al., 2009; Dityatev et al., 2010; Dansie
and Ethell, 2011). The ECM can be thought of as a scaﬀold
that surrounds neurons and glia within the extracellular space.
It is rich with signaling cues that can guide plasticity while
maintaining stable network connections over time, mediating
synaptic and trans-synaptic interactions. These components can
act as repulsive and/or attractive cues for cellular migration and
can mediate cell-ECM or cell–cell interactions. While the role
of ECM in the plasticity of neuronal circuits is not yet well
understood, cleavage of the ECM through the actions of matrix
metalloproteinases (MMP) and other ECM-cleaving enzymes
can drive plasticity in response to speciﬁc changes in neuronal
activity.
Matrix metalloproteinase-9 in particular stands out as an
important molecule in CNS development and plasticity. MMP-
9 is a Zn2+dependent endopeptidase expressed in both the
central- and peripheral nervous systems and acts to cleave
components of the ECM as well as cell adhesion molecules, cell
surface receptors and other proteases. Research has focused on
the role of MMP-9 in the progression of neurologic disorders
such as epilepsy, multiple sclerosis, neuroinﬂammatory and
autoimmune disorders. However, converging evidence suggests
that MMP-9 plays an important role in both establishing synaptic
connections during development and in the restructuring of
synaptic networks in the adult brain. As improper maturation
of sensory networks during development is implicated in
many neurodevelopmental disorders and in cognitive deﬁcits,
understanding the mechanisms of MMP-9 mediated synaptic
plasticity is essential for the development of therapeutic
strategies. Such knowledge will guide future clinical studies on
the possible role of MMP-9 in neurodevelopmental disorders. As
it is possible to regain a state of plasticity and reverse cognitive
deﬁcits by manipulating the onset and closure of ‘critical periods’
(Bradbury et al., 2002; Pizzorusso et al., 2002, 2006), regulating
MMP-9 activity during CPP may aid in further development
of precise and targeted treatments for neurodevelopmental
disorders.
MMP-9 Activity, Expression and
Regulation
Matrix metalloproteinase-9 is a Zn2+ dependent endopeptidase
that is found in many cell types throughout the body, including
neurons and glia, endothelial cells (Genersch et al., 2000),
glandular epithelia, supportive connective tissue, andmuscle cells
(Roomi et al., 2009). Among the 25 known MMPs (reviewed
by Ethell and Ethell, 2007), MMP-9, MMP-2 and MMP-3 are
widely expressed in the CNS. Furthermore, MMP-9 and MMP-
2 share similar substrate speciﬁcity and are known as gelatinases.
Their substrates include components of the ECM, as well as cell
adhesion molecules and cell surface receptors, cytokines, growth
factors, and other proteases (reviewed by Ethell and Ethell,
2007). Beside an active site containing Zn2+ that is necessary
for its enzymatic activity, MMP-9 also contains three ﬁbronectin
type II repeats which can directly bind gelatin, laminin and
collagens types I and IV (reviewed by Van den Steen et al.,
2002).
Matrix metalloproteinase-9 expression is regulated during
development, with high levels during early developmental time-
points that decrease into adulthood (Vaillant et al., 1999; Oliveira-
Silva et al., 2007; Bednarek et al., 2009; Aujla and Huntley, 2014).
This pattern is consistent when measuring either the protein
levels of MMP-9 with antibodies or the enzymatic activity levels
of MMP-9 using gelatin zymography (Oliveira-Silva et al., 2007).
Although MMP-9 levels remain low in the adult brain, MMP-
9 activity increases in response to synaptic activity (Gawlak
et al., 2009; Janusz et al., 2013). MMP-9 expression has been
detected in several brain areas, including the hippocampus
(Aujla and Huntley, 2014), the brainstem (Oliveira-Silva et al.,
2007), the cerebellum (Vaillant et al., 1999), and the neocortex
(Bednarek et al., 2009). MMP-9 proteolytic activity co-localizes
with excitatory synapses (Gawlak et al., 2009), while it’s mRNA
is detected within the cell body, along the processes and in
synaptoneurosome fractions of neurons (Janusz et al., 2013).
MMP-9 is also expressed in astrocytes, microglia and along
oligodendrocyte processes (reviewed by Dzwonek et al., 2004;
Gawlak et al., 2009).
Importantly, the expression, translation and activity of MMP-
9 are tightly regulated. Expression of MMP-9 can be regulated by
growth factors, cytokines, oncogenes, metal ions, and hormones
through MAPK pathway signaling (reviewed by Van den Steen
et al., 2002). MMP-9 translation is suppressed through its binding
to FMRP, an mRNA binding protein, implicating MMP-9 in
fragile X syndrome (FXS) (Janusz et al., 2013). MMP-9 mRNA
is mainly localized in the cell body of hippocampal neurons
and is translocated from the cell body to dendritic synapses
in response to neuronal activity (Dziembowska et al., 2012) as
a part of an FMRP containing granule (Janusz et al., 2013).
mGluR activation causes the dissociation of FMRP from the
MMP-9 mRNA (Janusz et al., 2013) followed by the association
of MMP-9 mRNA with actively translating polyribosomes and
de novo protein synthesis (Dziembowska et al., 2012). Once the
MMP-9 protein is secreted from a cell by a yet to be discovered
mechanism, it is in an inactive pro-from, also called a zymogen,
where its enzymatic activity is inhibited by a pro-domain that
masks the catalytic site through an interaction between Zn2+
and a cysteine residue in the pro-domain (reviewed by Ethell
and Ethell, 2007). This pro-form cannot cleave its substrates
until the pro-domain has been removed from the active site
by proteolysis or protein unfolding, a process called a cysteine
switch. This can be performed by other MMPs, serine proteinases,
by nitric oxide and by reactive oxygen species. The action of
MMP-9 is further limited by degradation of the enzyme and by
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inhibition of its activity via thrombospondins or through tissue
inhibitor of metalloproteinase-1 (TIMP-1) – which interestingly
is secreted in response to synaptic activity at levels similar to
MMP-9 (reviewed by Ethell and Ethell, 2007) and can form a
complex with MMP-9 prior to secretion (Roderfeld et al., 2007).
Thus, the tight regulation of MMP-9 activity is critical for its
function in development and plasticity, and highlights a role for
MMP-9 in cell-speciﬁc, activity-driven activation and remodeling
of the pericellular environment, with spatially and temporally
restrained eﬀects.
A large body of research on MMP-9 has focused on its
various roles in neurodegenerative disorders (reviewed by Yong,
2005). Nonetheless, it is becoming increasingly clear that MMP-
9 has multiple functions in CNS development as well, and may
contribute to neurodevelopmental disorders. MMP-9, through
cleavage of surface- and cell-adhesion molecules, is implicated
in active dendritic spine remodeling and stabilization (reviewed
by Bilousova et al., 2009; Benson and Huntley, 2012), aﬀecting
the shape and function of dendritic synapses (Michaluk et al.,
2011). MMP-9 also plays a role in pre- and postsynaptic
receptor dynamics (Michaluk et al., 2009; Peixoto et al., 2012;
Ning et al., 2013), in consolidation of long-term potentiation
(LTP; Wang et al., 2008), myelination (Oh et al., 1999), and
possibly in synaptic pruning (Wilczynski et al., 2008). It is
further implicated in axonal elongation (Shubayev and Myers,
2004), pathﬁnding (Vaillant et al., 2003; Lin et al., 2008; Aujla
and Huntley, 2014), regeneration (Ahmed et al., 2005) and
degeneration (Costanzo et al., 2006). This review summarizes
the various roles of MMP-9 in diverse developmental processes
within the CNS, with an emphasis on sensory development, and
suggests a role for misregulated MMP-9 in neurodevelopmental
disorders.
Brain Development and Critical Period
Plasticity
The critical period can be loosely deﬁned as a time when
experience-dependent activity can drive alterations in the
structure, functional organization and physiological properties
of brain regions. It occurs during postnatal development
and is marked by increased plasticity and massive synaptic
reorganization. The opening of the critical period is driven by
the onset of sensory function, when peripheral sensory structures
mature and begin to relay external sensory input into central
structures. Reorganization takes place among thalamocortical
projections, established prior to sensory input (reviewed
by Feller and Scanziani, 2005), and among corticocortical
connections, which together undergo increased synaptogenesis,
axonal arborization, and pruning (Sanes et al., 2005) so that each
sensory modality is able to respond optimally to behaviorally
relevant stimuli (reviewed by Hensch, 2004). This increased
plasticity during the critical period is time-limited, constrained
by the development of stabilizing factors such as increased
intracortical inhibition and the formation of PNNs, a specialized
ECM structure (reviewed by Hensch, 2005). The timing of this
plasticity is diﬀerent depending on species, sensory modality
and even on the type of sensory manipulation used within
a sensory modality (reviewed by Hensch, 2004). Non-sensory
regions likewise have a window of postnatal synaptogenesis,
reorganization, pruning and apoptosis (reviewed by Hashimoto
and Kano, 2005; reviewed by Ribak et al., 1985; Steward and
Falk, 1991; Luo, 2005; Murase and McKay, 2012). Periods of
high MMP-9 activity correlate with synaptic reorganization
during CPP and developmental windows across CNS regions (see
Table 1), suggesting a role for MMP-9 in shaping CPP kinetics.
Within this review we discuss CPP within rodent models due to
the widespread use of these models for genetic manipulation of
MMP-9 activity, and note that time-lines provided in this review
for CPP windows are subject to variability between experimental
procedures, protocols and outcome measures used, and are
intended as a basic guideline.
One of the ﬁrst demonstrations of CPP came from studies
by Hubel and Wiesel (1964) in the kitten visual cortex, where
they demonstrated that monocular deprivation alters both
functional and anatomical organization in the cortex and, to
a more limited extent, in the thalamus. Within the rodent
visual cortex, the CPP window opens during the third postnatal
week and closes into the ﬁfth postnatal week, with adult-like
functional properties by P45 (Fagiolini et al., 1994; Gordon
and Stryker, 1996), though retinotectal reorganization occurs
mostly in the ﬁrst three postnatal weeks (Serfaty et al., 2005;
Oliveira-Silva et al., 2007). Most neurons in the rodent visual
cortex (Sawtell et al., 2003) and SC respond to contralateral eye
stimulation and this contralateral preference can be manipulated
during development by monocular deprivation. After eye closure
(monocular deprivation), there is a reorganization of network
connections contralateral to the deprived eye within the visual
cortex (Spolidoro et al., 2012) and SC (Oliveira-Silva et al., 2007).
Neuronal responses to stimulation of the deprived eye undergo
depression and weakening of synaptic eﬃcacy within 3 days
(Sawtell et al., 2003), along with shrinkage of thalamocortical
projections (reviewed by Feller and Scanziani, 2005; Spolidoro
et al., 2012). Between 4 and 7 days after monocular deprivation,
responses to the non-deprived eye undergo potentiation, with
a concomitant expansion in axonal arborization (reviewed by
Sawtell et al., 2003; Feller and Scanziani, 2005; Spolidoro et al.,
2012). The overall outcome is that more neurons will respond to
visual stimulation of the non-deprived ipsilateral eye, termed an
ocular dominance shift.
Matrix metalloproteinase-9 has been implicated in various
aspects of visual CPP. In the SC, MMP-9 enzymatic activity
and protein levels (both the proform and active forms) are
high during the period of retinotectal map reorganization before
and just after eye opening (from P0 to P14), and decrease
during late (P21–P42) postnatal development (Oliveira-Silva
et al., 2007). Broad inhibition of MMPs from P0 to P7 alters
the topographical organization of retinotectal terminals, while
monocular enucleation at P10 increases MMP-9 enzymatic
activity in the SC both contralateral and ipsilateral to the
enucleated eye (Oliveira-Silva et al., 2007). Within the cortex,
MMPs are involved in plasticity following monocular deprivation
for either 3 or 7 days in adolescent rats (P21–P45; Spolidoro et al.,
2012). Inhibition of MMP activity, using the broad spectrum
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TABLE 1 | Matrix metalloproteinase-9 expression in CNS development.
Brain region Developmental window Peak of MMP-9 expression MMP-9 in experience
dependent plasticity
Reference
Retinotectal
Axons
Visual Cortex
Optic Nerve
Retinotectal map formation:
P0–P21 (first 3 postnatal weeks) r.
Monocular deprivation:
P21–P28 r.;
Postnatal week 3–5 r.;
P19–P32 m.
Optic nerve myelination:
P7–P9 m.
Sup. Colliculus:
P0–P10 protein
P0–P14 activity.
Optic Nerve:
P7-P11 activity.
P7 mRNA
Monocular enucleation increases
MMP-9 enzymatic activity in SC
Monocular deprivation increases
MMP-9 mRNA in cortex
Oliveira-Silva et al. (2007)
Fagiolini et al. (1994), Gordon
and Stryker (1996), Spolidoro
et al. (2012)
Oh et al. (1999), Larsen et al.
(2006)
Barrel Cortex Thalamocortical input to Layer 4:
P1-P4/5 m., r.
Intracortical connections: Layer
4-2/3: P10-P14 r. Layer 2/3: thru
adulthood r.
Whisker trimming in adolescent
mice increases MMP-9 enzymatic
activity; MMP-9 KO mice show
reduced potentiation in L4 and L2/3
following trimming
Woolsey and Wann (1976),
Kossut et al. (1988), Fox
(1992), Maravall (2004),
Kaliszewska et al. (2012)
Cerebellum Granule cell proliferation, Climbing
fibers refinement:
Postnatal week 1
Granule cell migration; Parallel fiber
innervation of Purkinje cells:
Postnatal week 2–3
Purkinje cell arborization:
Postnatal week 4
Granule precursors, Bergmann
glia, Purkinje cells: P10 protein
EGL, IGL and Purkinje cell
layer: P11-P17 protein
MMP-9 KO mice at P12 exhibit:
Decreased apoptosis of granule
precursor cells;
Delay in granule cell migration
r. Altman (1972a,b), r. Vaillant
et al. (1999), r. Piccolini et al.
(2012), m. Vaillant et al. (2003)
Hippocampus Spontaneous activity and
apoptosis: P0–P7 r. m.
Mossy fiber development: first
postnatal month r.
Synapse elaboration: first postnatal
month r.
Axon tips: P4 r. protein
DG, CA1, CA3: P4 r. mRNA
Postsynaptic densities: P8 r.
protein
MMP-9 mediates cell survival
through interactions with laminin
MMP-9 KO mice show accelerated
synaptic maturation
MMP-9 treatment exaggerates
immature spine morphology
Ribak et al. (1985), Steward
and Falk (1991), Bilousova et al.
(2009), Murase and McKay
(2012), Aujla and Huntley
(2014), Sidhu et al. (2014)
Auditory Cortex Tonotopic reorganization:
P11–P15 m.
P11–P13 r.
P9–P20 m.
P11–P28 r.
Cochleotomy leads to increased
MMP-9 levels in cochlear nucleus
1 day post-op
Zhang et al. (2002),
de Villers-Sidani et al. (2007),
Illing et al. (2010),
Barkat et al. (2011),
Kim et al. (2013)
r., rats; m., mouse; activity, enzymatic activity measure by zymography.
MMP inhibitor GM6001 produces three main eﬀects: (1) reduces
the ocular dominance shift after monocular deprivation by
selectively preventing the potentiation of open-eye responses
without aﬀecting the depression of deprived-eye responses, (2)
blocks the deprivation-driven increase in spine density in layer
2/3 excitatory neurons contralateral to the deprived eye, and
(3) blocks the potentiation of the deprived-eye responses after
eye reopening. Though MMP-9 cannot be directly implicated
in cortical ocular dominance plasticity based on these results,
the authors noted that the only MMP to show mRNA changes
in response to monocular deprivation was MMP-9 (Spolidoro
et al., 2012). MMP-2 is, however, expressed in the CNS at
higher basal levels than MMP-9, and therefore may account for
ocular dominance plasticity without mRNA up-regulation. To
our knowledge there is no published work using MMP-9 KO
mice to further test the role of MMP-9 in visual CPP, however,
MMP-3 KO mice, which have reduced activation of pro-MMP-9,
do demonstrate altered visual CPP plasticity including reduced
open-eye potentiation, suggesting a possible role for MMP-9
(Aerts et al., 2014).
Matrix metalloproteinase-9 has been more directly implicated
in somatosensory barrel cortex plasticity. In rodent barrel cortex
each whisker is represented in a one-to-one ratio by a cortical
cellular aggregate, termed a ‘barrel.’ Both the thalamocortical
innervation of the barrels as well as the intracortical connections
can be modiﬁed by removing the whiskers, with less dramatic
reorganization after plucking or trimming of the whiskers.
There are multiple windows of plasticity between cortical layers
and across ages (reviewed by Fox, 2002), and the eﬀect of
experimental manipulation on barrel cortex plasticity depends
both on the age, length and the type of manipulation used.
Early postnatal CPP takes place largely in layer IV barrel cortex
from P0 to P4/5 (Woolsey and Wann, 1976; Fox, 1992). It
is characterized by receptive ﬁeld plasticity, a conversion of
silent synapses into active synapses, and changes in pre-synaptic
thalamocortical arborization and barrel formation (reviewed
by Fox, 2002 and Erzurumlu and Gaspar, 2012). Lesions
within this window can induce structural reorganization of
thalamocortical aﬀerents (reviewed by Fox, 2002; Erzurumlu
and Gaspar, 2012). CPP in layer IV to II/III occurs from P10
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to P14 (reviewed by Maravall, 2004; Erzurumlu and Gaspar,
2012), whereas horizontal intracortical connections in layers
II/III remain plastic through the third postnatal week and,
to a lesser extent, throughout adolescence (reviewed by Fox,
2002). Adolescent plasticity is characterized as functional but
not structural reorganization, including potentiation of spared
input and depression of deprived input. More limited functional
plasticity remains into adulthood (reviewed by Kossut et al., 1988;
Fox, 2002).
One common manipulation to examine barrel CPP is to
trim all but one row of whiskers. This can cause a topographic
reorganization of functional sensory maps so that barrel columns
in the cortex that have been deprived of peripheral sensory input
will respond to deﬂections of the retained, intact whiskers. Such
reorganization is possible in adolescent mice after 1 week of
whisker trimming, and even more pronounced after 4 weeks.
This manipulation causes an increase in the width of barrel
activation when the spared-whiskers are deﬂected, an eﬀect seen
in all cortical layers of a vertical barrel column (Kaliszewska
et al., 2012). When the spared-whisker is deﬂected there is also
increased cellular activation in the barrel columns that directly
border the spared row, as measured by c-fos density (Kaliszewska
et al., 2012). After undergoing this deprivation-induced plasticity
for 1 week, MMP-9 enzymatic activity levels are higher in
the barrel cortex of mice when compared to the control non-
deprived hemisphere, whereas there is no increase in MMP-2
(Kaliszewska et al., 2012). In MMP-9 KO mice, though 4 weeks
of deprivation did increase the width of spared-row activation in
all cortical layers when compared to the control non-deprived
hemisphere, the width of layer IV activation was signiﬁcantly
smaller than in WT mice (Kaliszewska et al., 2012). Cellular
activation of the deprived rows was also signiﬁcantly reduced in
layer II/III of MMP-9 KO mice compared to WT mice, but was
no diﬀerent in any other layer (Kaliszewska et al., 2012). The fact
that MMP-9 activity did not aﬀect reorganization at all layers
indicates a speciﬁc action of MMP-9, though the mechanism of
the speciﬁcity is not known.
Understanding how MMP-9 is aﬀecting plasticity at only
certain levels of the circuit is diﬃcult based on these results.
The most likely site of functional reorganization in adult barrel
cortex after deprivation or denervation may be through the
unmasking of previously established silent or ‘weak’ synapses
that project from the intact whisker onto neighboring columns
(Simons, 1978; Kossut et al., 1988). It is possible that MMP-
9 is necessary for integrating these weaker synapses into the
circuit by maturation and stabilization of synaptic contacts
(see Synapse Development and Plasticity below). Conversely,
increased responses to the intact whisker column may be due to
disinhibition from surrounding barrels (Kelly et al., 1999). The
decreased potentiation in layer II/III observed in the deprived
neighboring barrel columns in MMP-9 KOmice may be an eﬀect
of the reduced potentiation in layer IV of the intact barrel, as
measurement of response latency suggests that information is
transferred within a barrel column ﬁrst, beginning in layer IV
and transferring vertically between layers, before it is transferred
outward to neighboring barrels (Armstrong-James et al., 1992;
reviewed by Fox, 2002; Feldmeyer, 2012). It is further possible
that the increased functional activation in layer IV was reﬂective
of changes in astrocytic activity instead of or in addition to
neuronal activity. The method of 2-DG autoradiography used in
Kaliszewska et al. (2012) measures metabolic activity including
that of astrocytes which are located within the somatosensory
barrel cortex and which show an organizational pattern that
parallels neuronal organization (Giaume et al., 2009; Logvinov
et al., 2011). It is possible that loss of MMP-9 can aﬀect
astrocytic function and that as-yet undetermined interactions
exist between astrocytes, MMP-9 activity and synaptic plasticity
in layer IV barrel cortex. More studies are needed to clarify
the mechanisms that underlie changes in plasticity observed
here.
To our knowledge, no studies have looked at the role of
MMP-9 in auditory system CPP. MMP-9 does not inﬂuence the
development of spiral ganglion cells, which relay information
from cochlear hair cells to the CNS (Sung et al., 2014). On the
other hand, after removal of the cochlea and spiral ganglion
cells, MMP-9 protein in the cochlear nucleus peaks 1 day post-
operation, with an increase in the neuropil and a decrease
within cell bodies, suggestive of increased MMP-9 secretion
from the cells and indicating that MMP-9 may be involved
in degenerative and/or regenerative processes in early auditory
pathways (Illing et al., 2010). Indirect evidence suggests MMP-
9 may have a role in auditory CPP. In Fmr1 KO mice, a
mouse model of FXS, auditory cortex CPP is deﬁcient (Kim
et al., 2013). MMP-9 enzymatic levels are elevated in the brain
of Fmr1 KO mice (Gkogkas et al., 2014; Sidhu et al., 2014)
possibly due to a loss of FMRP transcriptional regulation of
MMP-9 (Janusz et al., 2013). Genetic deletion of MMP-9 or
pharmacological treatment that lowers MMP-9 levels during
postnatal development rescues behavioral deﬁcits in Fmr1 KO
mice in adulthood (Dansie et al., 2013; Sidhu et al., 2014).
Therefore, it is possible that elevated MMP-9 underlies deﬁcient
auditory cortex CPP in the Fmr1 KO mice, which remains to
be tested. This is an important avenue of research because CPP
deﬁcits may underlie later auditory processing deﬁcits in FXS
patients (Rotschafer and Razak, 2013; reviewed by Rotschafer and
Razak, 2014).
In the rodent cerebellum, a peak in MMP-9 expression also
correlates with a window of synaptic and cellular reorganization.
The cerebellum has a clear laminar distribution of cell types
and function, with a deep layer called the granular layer or
internal granular layer (IGL), a middle layer called the Purkinje
cell layer, and a superﬁcial layer called the molecular layer.
During early postnatal development there is yet another layer
which covers the surface of the cerebellum, the external granular
layer (EGL). Cerebellar postnatal development is marked ﬁrst
by the proliferation of cerebellar granule neuron precursor cells
in the EGL during the ﬁrst postnatal week (Altman, 1972a;
reviewed by Luo, 2005) and a reﬁnement of climbing ﬁber
excitatory input onto Purkinje cells (reviewed by Hashimoto and
Kano, 2005). During the second postnatal week the EGL thins
following the migration of granule precursor cells (Vaillant et al.,
1999) and disappears by the end of the third postnatal week.
During this same time frame the reﬁnement of climbing ﬁber
connections onto Purkinje cells is followed by the innervation
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of parallel ﬁbers (granule cell axons) onto Purkinje cells as the
Purkinje cells begin to form secondary and tertiary dendritic
branches (Altman, 1972b; reviewed by Hashimoto and Kano,
2005). Finally Purkinje cells undergo an extensive arborization
during the fourth postnatal week (reviewed by Luo, 2005).
MMP-9 enzymatic activity peaks at P10 and decreases to adult
levels by P15 (Vaillant et al., 1999). MMP-9 protein at P10
is detectable in granule precursor cells, Bergmann glial cell
bodies and processes, and in Purkinje cell dendrites, a pattern
which is similar to MMP-9 mRNA expression (Vaillant et al.,
1999). From P11 to P17, both MMP-9 and MMP-3 protein are
expressed in the EGL, the IGL, and intensely in the molecular
and Purkinje cell layers (Piccolini et al., 2012) where MMP-9
labels the soma of granule and Purkinje cells (Vaillant et al.,
2003). At P12 MMP-9 expression in the EGL is concentrated in
the premigratory pool of granule precursor cells and is present
in migrating granule precursor cells dispersed in the molecular
layer (Vaillant et al., 2003). Overlapping expression of MMP-9
and MMP-3 is important because MMP-3 can cleave and activate
MMP-9. Indeed, MMP-9 plays an important role in cerebellar
development as the application of an MMP-9 blocking antibody
and genetic deletion ofMMP-9 inhibit axonal outgrowth (parallel
ﬁbers) and the migration and apoptosis of granule cell precursors
in the developing cerebellum (Vaillant et al., 2003).
In the hippocampus, structural organization is largely
established during embryogenesis, though in the germinal zone of
the DG active neurogenesis and granule cell migration continue
into adulthood (Bayer, 1980). During the ﬁrst postnatal week,
there is spontaneous activity that drives reorganization and
neuronal survival (Murase and McKay, 2012), while mossy
ﬁbers (Ribak et al., 1985) as well as synapses within the DG
and CA1 (Steward and Falk, 1991) undergo elaboration and
maturation throughout the ﬁrst postnatal month. At P4, MMP-
9 mRNA levels peak in the DG, CA1 and CA3, and MMP-
9 and MMP-2 proteins are shown to co-immunolabel with
L1CAM (L1 cell adhesion molecule), a marker of growing axons
(Aujla and Huntley, 2014). At a period of peak hippocampal
synaptogenesis, MMP-9 and MMP-2 are localized near the
postsynaptic densities immunolableled against PSD-95 (Aujla
and Huntley, 2014). MMP-9 genetic deletion accelerates the
maturation of dendritic spines showing an early increase in
the number of mature mushroom-shaped spines at P8, which
is normally observed later at P14–P21 (Sidhu et al., 2014).
Conversely, an acute treatment of cultured hippocampal neurons
with active MMP-9 leads to an increase in immature ﬁlopodia-
like spines and a decrease in mature mushroom-shaped spines
(Bilousova et al., 2009). While global genetic deletion of MMP-
9 causes an increase in the number of mature spines during
early postnatal hippocampal development and enhanced MMP-
9 activity leads to the formation of immature spines in cultured
hippocampal neurons, a transient release of MMP-9 at the level
of a single synapse was shown to be associated with LTP-induced
spine enlargement in adult hippocampus (Wang et al., 2008; see
Synapse Development and Plasticity for more details). MMP-9
has been also implicated in spine head maturation during the
development of visual cortex (Kelly et al., 2014). It is possible
that genetic deletion of MMP-9 can lead to brain area speciﬁc
compensatory eﬀects of other MMPs (Esparza, 2004; Nagy et al.,
2006), as MMP-3 is also expressed in the brain and is implicated
in synaptic plasticity (Aerts et al., 2014).
Taken together, these studies suggest MMP-9 activity
contributes to multiple aspects of neural network reorganization
during early development, including regulation of CPP plasticity.
This sensory-dependent, activity driven reorganization primes
each region to respond appropriately to external cues. The
mechanisms underlying MMP-9-mediated CPP and synaptic
reorganization though, are not well understood (see Table 2).
Cellular Mechanisms
Synapse Development and Plasticity
The structural changes within the CNS thought to underlie neural
plasticity, including learning and memory, can be traced to the
TABLE 2 | Matrix metalloproteinase-9 role in specific plastic events.
Reference
Synaptic Plasticity
Late-phase LTP Nagy et al. (2006), Okulski et al. (2007), Wang et al. (2008), Wiera et al. (2013)
NMDA receptor trafficking Michaluk et al. (2009)
AMPA receptor trafficking Szepesi et al. (2014)
Spine elongation Bilousova et al. (2009), Michaluk et al. (2009, 2011)
Spine maturation Wang et al. (2008), Kelly et al. (2014), Szepesi et al. (2014)
Integrin-dependent Wang et al. (2008), Michaluk et al. (2009, 2011)
Involves ICAM-5 Tian et al. (2007), Ning et al. (2013), Kelly et al. (2014)
Axonal plasticity
Pathfinding Vaillant et al. (2003), Hehr (2005), Aujla and Huntley (2014)
Regeneration after injury Ferguson (2000), Shubayev and Myers (2004), Ahmed et al. (2005)
Degeneration after injury Costanzo et al. (2006)
EphB2 mediated growth cone collapse Lin et al. (2008)
Myelination
Oligodendrocyte process extension/formation Uhm et al. (1998), Oh et al. (1999), Šišková et al. (2009)
Oligodendrocyte/axon contact Maier et al. (2006)
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level of the individual synapse and spine. Functional synaptic
plasticity can be broadly classiﬁed into two underlying processes:
one being depression, during which the post-synaptic potentials
are reduced in amplitude relative to baseline, and the other being
potentiation, characterized as an increase in synaptic strength.
Additionally these changes in synaptic eﬃcacy can be transient
(short-term) or they can be maintained hours to days (long-
term), where modiﬁcation of receptors at synaptic sites through
new protein synthesis is thought to underlie long-term changes.
The mechanisms of both potentiation and depression can be
localized to the presynaptic axon terminal, the postsynaptic
dendrite, or both. Synaptic plasticity is a process that can
incorporate new or changing input into a system, can form
associative networks of connections and can respond to changes
in the nervous system environment by scaling connections up or
down over time to allow for ﬁne-tuned network modiﬁcation. As
such, synaptic plasticity can be considered to be a fundamental
cellular event underlying much of the ability of the brain to adapt
and respond to changing environmental demands throughout
a lifetime, from CPP sensory reorganization to learning and
memory.
Matrix metalloproteinase-9 has been implicated in the
maintenance of LTP. LTP can be classiﬁed into an early-
phase LTP (e-LTP) that is independent of protein synthesis
and a late-phase LTP (l-LTP) that requires new protein
synthesis. l-LTP in particular may underlie the consolidation
of memories by strengthening synapses for extended periods
of time. A popular brain structure for the study of synaptic
plasticity mechanisms is the hippocampus, due to its well-deﬁned
circuit organization and because of its role in learning and
memory. Multiple hippocampal pathways have been used to
study the role of MMP-9 in synaptic plasticity. In the mossy
ﬁber-CA3 pathway, LTP induction in adolescent rats causes
an increase in MMP-9 enzymatic activity, both the proform
and the active form of the enzyme, and an increase in MMP-
9 protein expression in CA3 neurons (Wiera et al., 2012).
Both total genetic deletion of MMP-9 (mice) and a 15-fold
overexpression of MMP-9 (rats) impair the maintenance of LTP
in the mossy ﬁber-CA3 pathway in hippocampal adolescent slices
(Wiera et al., 2013). In both MMP-9 KO and overexpressing
models the initial potentiation after high frequency tetanic
stimulation is comparable to wild types, but as early as 7–
10 min post-stimulation, both models show a signiﬁcantly
reduced potentiation (Wiera et al., 2013). This indicates that
too much or too little MMP-9 can lead to impaired LTP
maintenance, including both early- and late-phase LTP. In
a diﬀerent hippocampal pathway, the Schaﬀer collateral-CA1
pathway, MMP-9 activity is also implicated in LTP. High
frequency tetanic stimulation or chemically induced LTP (cLTP)
increase the levels of active MMP-9 protein, peaking 30 min
post-stimulation, but do not aﬀect the levels of MMP-2 (Nagy
et al., 2006). cLTP also increases the proteolytic activity of
MMP-9 localized to the neuropil in CA1 stratum radiatum
(Nagy et al., 2006). Inhibition of MMP-9 and MMP-2 in slices
of both young and adult rats, or inhibition of MMP-9 alone
in anesthetized rats in vivo (Bozdagi et al., 2007), does not
aﬀect initial potentiation and e-LTP but does impair l-LTP,
with decreased potentiation by 60 min post-stimulation (Nagy
et al., 2006). Total genetic deletion of MMP-9 in this same
pathway impairs LTP overall, similar to the mossy ﬁber-CA3
pathway (Nagy et al., 2006). In the CA1 to prefrontal cortex
pathway TIMP-1 overexpression, which reduces MMP activity,
prevents l-LTP in vivo (Okulski et al., 2007). Similarly direct
inhibition of MMP-9 in vitro blocks prefrontal l-LTP but not
e-LTP (Okulski et al., 2007). The precise mechanisms by which
MMP-9 aﬀects synaptic plasticity are not fully understood. In the
Schaﬀer collateral-CA1 pathway, increased MMP-9 levels after
tetanic stimulation were dependent on N-methyl-D-aspartate
(NMDA) receptor activation at postsynaptic sites (Nagy et al.,
2006). Conversely in the mossy ﬁber-CA3 pathway, where LTP
is also MMP-9 dependent, LTP occurs at presynaptic sites
and is independent of NMDA receptors (Harris and Cotman,
1986; Castillo et al., 1997; Wiera et al., 2013). Moreover the
experimental manipulations used to test MMP-9 necessity, by
either genetic deletion or chemical inhibition, have diﬀerential
eﬀects on e-LTP induction, leaving in question the role of MMP-9
in e-LTP.
Matrix metalloproteinase-9 also aﬀects the traﬃcking of
both NMDA and α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate (AMPA) glutamate receptors. The modiﬁcation
and/or insertion of glutamate receptors to the postsynaptic
site are thought to fundamentally relate to long-term synaptic
plasticity. Bath application of auto activating MMP-9 in
cultured hippocampal neurons induces the lateral diﬀusion of
NMDA receptors, but not GluA2-containing AMPA receptors,
at synapses (Michaluk et al., 2009). On the other hand, after
a chemical LTP (cLTP) induction in cultured hippocampal
neurons, MMP activity is necessary for the immobilization
and synaptic accumulation of GluA1- and GluA2-containing
AMPA receptors (Szepesi et al., 2013, 2014) in dendritic spines.
MMP-9 in particular was suggested to be involved in AMPA
receptor traﬃcking because MMP-9 levels, but not MMP-2,
were up-regulated following cLTP (Szepesi et al., 2013). The
action of MMP-9 on lateral diﬀusion of NMDA receptors
was shown to depend on integrin β1 signaling (Michaluk
et al., 2009). Integrins are membrane-bound ECM receptors
found on pre-and postsynaptic sites in many types of cells
in the CNS. Activation of integrin receptors induces the
elongation of dendritic spines in hippocampal culture (Shi
and Ethell, 2006). Longer, thinner spines are associated with
immature synapses and are highly motile, whereas shorter
spines with large spine heads are associated with mature,
stable synaptic connections. MMP-9 transgenic overexpression
or global bath application of active MMP-9 induces the
elongation of dendritic spines, similar to integrin activation,
while blocking integrin receptors prevents MMP-9-induced
spine alterations (Bilousova et al., 2009; Michaluk et al., 2011).
The eﬀects of MMP-9 on integrin receptor signaling are not
mediated through direct protein–protein interactions (Michaluk
et al., 2009). Rather it is suggested that MMP-9 cleavage
of ECM triggers a release of RGD-containing peptides that
are potent activators of integrins (Ruoslahti, 1996b). A direct
application of RGD-containing peptide to cultured hippocampal
neurons was also shown to induce spine elongation and actin
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reorganization in dendritic spines in an NMDA-dependent
manner (Shi and Ethell, 2006), possibly through integrin-
mediated phosphorylation of NMDA receptors (Bernard-Triﬁlo
et al., 2005).
Interestingly, local activation of MMP-9 at the level of
individual synapses can induce the maturation of spine heads
instead of spine elongation. After cLTP in culture, MMP-9
(and possibly MMP-2) enzymatic activity is localized around a
small number of immature spines that preferentially undergo
spine head enlargement (as opposed to already mature spines;
Szepesi et al., 2014). Additionally, experiments using theta
burst stimulation to induce LTP in acute hippocampal slices
demonstrated that MMP-9 activity is both necessary and
suﬃcient to induce expansion of spine heads, including small
and large spines (Wang et al., 2008). Blocking MMP activity
produced a transient increase in head size that was quickly
reduced to baseline, analogous to the MMP-9 dependent
maintenance of LTP (Nagy et al., 2006; Okulski et al., 2007;
Wang et al., 2008). Consistent with other reports, MMP-
9-mediated spine head enlargement was also dependent on
integrin signaling (Wang et al., 2008). In addition, both MMP-
9 activation and cLTP were shown to induce the extension of
ﬁlopodia-like protrusions from the heads of dendritic spines
(Szepesi et al., 2013), which were also linked to a local change
in connectivity in response to glutamate release (Richards
et al., 2005). Taken together this indicates that MMP-9 can
induce spine elongation or maturation depending on the level
of MMP-9 activity, its localization and/or substrate. Why
MMP-9 would have such diﬀerential eﬀects is unclear. If
endogenous MMP-9 does preferentially target immature spines
to induce their maturation in response to neuronal activity
(Szepesi et al., 2014), exogenous application of MMP-9 could
disrupt this selectivity, targeting mature synapses instead. It is
likewise possible that MMP-9 cleavage of speciﬁc synaptic and
perisynaptic targets at a speciﬁc time and place is necessary for
spine head enlargement, but that if the action is not temporally
restricted MMP-9 activity prevents these synaptic structures
from maturing and stabilizing. Indeed, both genetic deletion and
overexpression of MMP-9 impairs the maintenance of LTP in
the mossy ﬁber-CA3 pathway in hippocampal slices (Wiera et al.,
2013).
Matrix metalloproteinase-9 up-regulation in response to
NMDA activity can also act on ICAM-5 and NLG-1 to
regulate dendritic spine morphology. ICAM-5 is a cell adhesion
molecule found in excitatory cell bodies and in dendritic
shafts and spines. In cultured hippocampal neurons, ICAM-
5 is found in association with thin spines and ﬁlopodia more
so than with mature mushroom-shaped spines (Tian et al.,
2007; Ning et al., 2013). ICAM-5 within postsynaptic ﬁlopodia
binds to presynaptic β1integrin receptors to mediate trans-
synaptic signaling and this binding maintains immature spine
morphology (Ning et al., 2013). Hippocampal neurons treated
with NMDA show an increase in mushroom shaped spines
with a concomitant increase in ICAM-5 cleavage, indicating that
cleavage of ICAM-5 may induce spine maturation (Tian et al.,
2007). Both MMP-9 and MMP-2 can cleave ICAM-5, and active
levels of both enzymes are elevated after NMDA stimulation
(Tian et al., 2007). Likewise, NMDA induced cleavage of ICAM-
5 in dendritic shafts is rescued by inhibition of MMP-2 and
MMP-9 (Tian et al., 2007). In the visual cortex during a period
of active synaptogenesis, just prior to (P14) and during ocular
dominance CPP (P28), there is a developmental shift in ICAM-
5 localization from dendritic protrusions at P14 to dendritic
shafts by P28 (Kelly et al., 2014). However, this shift does not
occur in MMP-9 KO mice (Kelly et al., 2014). Instead there are
increased ICAM-5 levels in dendritic protrusions at both P14
and P28 which do not change with age (Kelly et al., 2014). An
increase in synaptic contacts between ICAM-5 labeled structures
(presumably dendritic structures) and axon terminals is also
observed in MMP-9 KO mice (Kelly et al., 2013). Together
this may indicate that MMP-9 cleaves ICAM-5 in response to
NMDA stimulation to induce spine maturation, while in the
absence of MMP-9 ICAM-5 remains in dendritic protrusions
and maintains immature synapses through its binding to
presynaptic β1 integrin receptors. NLG-1 is a postsynaptic
adhesion molecule, speciﬁc to excitatory cells, which binds
to presynaptic neurexins through trans-synaptic interactions
(Peixoto et al., 2012). MMP-9 cleaves NLG-1 both in vivo and
in vitro, and this cleavage induces a rapid destabilization of
its presynaptic partner neurexin-1 (Peixoto et al., 2012). This
destabilization is paralleled by a reduced frequency of mini
excitatory postsynaptic potentials and an altered paired pulse
ratio – indicative of reduced presynaptic release probability
(Peixoto et al., 2012). MMP-9 cleavage of NLG-1 is dependent
on NMDA activation and Ca2+/calmodulin-dependent protein
kinase signaling, and occurs locally at the excited spine (Peixoto
et al., 2012). Interestingly, NLG-1 cleavage is also regulated by
sensory experience associated with CPP in the visual cortex and
is increased within 2 h of light exposure after 5 days of light
deprivation (dark rearing) in mice during the fourth postnatal
week (Peixoto et al., 2012). Together these studies illustrate
a role for MMP-9 in the active modiﬁcation of postsynaptic
sites to modulate synaptic eﬃcacy, a process important both
during development and throughout adulthood. However, the
role of MMP-9 in presynaptic axon reorganization remains less
clear.
Axon Regeneration and Plasticity
The basic pattern of axonal tract organization is largely
established before birth. During embryonic development axonal
processes migrate through the developing nervous system
relying on chemical cues as well as cell–cell and matrix–
cell interactions in order to ﬁnd their target locations. They
then undergo reorganization in response to sensory stimulation
during the critical period, where there is an elaboration of
axonal arborizations followed by pruning. The axon arbors
are thought to remain relatively stable after CPP closure,
but can undergo reorganization following injury or sensory
deprivation. MMP-2 and MMP-9 have been implicated in
embryonic axon path ﬁnding in the Xenopus (Hehr, 2005) and
MMP-9 was more directly implicated in regeneration of axons
after injury in the rat (Shubayev and Myers, 2004; Ahmed
et al., 2005). MMP-9 protein is also expressed in growing axons
during early postnatal synaptogenesis in the hippocampus (Aujla
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and Huntley, 2014) and is necessary for neurite outgrowth
in cerebellar granular cells (Vaillant et al., 2003). Still, the
role of MMP-9 in CPP axonal reorganization needs further
investigation.
During axon outgrowth and regeneration, MMP-9 activity
seems to have diﬀerential eﬀects depending on the neuronal
type. MMP-9 protein is localized to axon growth cones in
regenerating nerve ﬁbers 8 days after sciatic nerve injury in rats
(Shubayev and Myers, 2004) and its active enzymatic activity
can peak as soon as 21 h after sciatic nerve injury in the
mouse (Ferguson, 2000), although this early increase may be
associated with inﬂammatory processes at the injury site rather
than with regeneration per se. MMP-9 in PC12 cell culture
can increase the length of sprouting ﬁbers without aﬀecting
the total number of sprouting ﬁbers (Shubayev and Myers,
2004). Similarly, MMP-9 and MMP-2 treatment of dorsal root
ganglion neurites grown in culture can increase the average
length of the neurites (Ferguson, 2000). Conversely, MMP-
9 treatment does not aﬀect either the number or the length
of neurites in neonatal spiral ganglion neurons cultured from
5 days old rats (Sung et al., 2014). After olfactory nerve injury,
increases in MMP-9 protein levels overlap with degeneration
of mature olfactory neurons, while MMP-9 decreases during
the period of regeneration (Costanzo et al., 2006). In contrast,
both MMP-9 and MMP-2 protein and enzymatic levels are
increased in regenerating optic nerves compared to non-
regenerating nerves, peaking 8 days after injury (Ahmed et al.,
2005).
Mechanisms underlying MMP-9 activity in axon growth
and repair are also diverse. MMP-9 and MMP-2 can cleave
EphB2, a receptor tyrosine kinase that can diﬀerentially attract
or repulse axonal ﬁbers through interactions with the ephrin-
B ligand (reviewed by Sloniowski and Ethell, 2012). MMP-9
cleavage of EphB2 triggers a cell repulsion and subsequent
collapse of axon growth cones in cultured hippocampal neurons
through Rho GTPase activation (Lin et al., 2008). Additionally,
MMP-9 cleaves CRMP-2 (Bajor et al., 2012), a protein that
is shown to induce neuronal polarization and the elongation
of axons (Yoshimura et al., 2005) in part through its ability
to bind with tubulin heterodimers and to thereby promote
microtubule formation (Fukata et al., 2002). How MMP-
9 activity might aﬀect the function of CRMP-2 is not yet
clear, though the putative cleavage site for MMP-9 of CRMP-
2 overlaps with its protein binding site (Bajor et al., 2012),
indicating that MMP-9 cleavage might interfere with CRMP-
2 binding to tubulin, thereby aﬀecting axonal elongation.
Furthermore, MMP-9 can create a permissive environment for
nerve regrowth after injury by controlling the proliferation of
Schwann cells through induction of the Ras/Raf/MEK–ERK
pathway to suspend Schwann cell mitosis (Chattopadhyay and
Shubayev, 2009). Together these studies indicate numerous roles
for MMP-9 in axonal plasticity, including regeneration and
degeneration after injury, polarization and growth of neurite
ﬁbers, axon repulsion and growth cone collapse, as well as
interactions with glial cells. It remains to be seen whether
similar mechanisms play a role in postnatal CNS development
and CPP.
Myelination
Matrix metalloproteinase-9 is also expressed in OL (Oh et al.,
1999) and MMP activity is implicated in the regulation of myelin
formation in the CNS (Maier et al., 2006). Myelination is one of
the last processes to occur in CNS development, a hallmark of
mature, established axonal connections. In the CNS, myelination
along axonal processes is performed by OL, a type of glial cell.
Each oligodendrocyte can myelinate as many as 40 internodes,
a process that occurs in several steps. After OL migrate and
proliferate during early postnatal development (reviewed by
Pfeiﬀer et al., 1993) three further steps are involved in the
process of myelination: (1) OLs begin a period of extensive
outgrowth of processes radially from the cell body toward the
axons, (2) once contact with an axon has been made, the OL
ensheaths the axon in myelin layers until (3) compaction of
the myelin sheath occurs (Uhm et al., 1998). Neuronal signals
are key in the maturation of OL, where for example adenosine
acts as a neuron-glial signal to inhibit the proliferation of
OL progenitor cells and promote diﬀerentiation and myelin
formation (Stevens et al., 2002). Myelin formation peaks within
the ﬁrst 4 weeks after birth (Foran and Peterson, 1992), generally
in a caudal to rostral organization (reviewed by Pfeiﬀer et al.,
1993). Axons with larger diameters are myelinated ﬁrst, followed
by smaller-diameter axons (Matthews and Duncan, 1971; Ye
et al., 1995b). However, there are speciﬁc periods of myelination
within diﬀerent brain regions, each with a speciﬁc onset/peak
window as well as diﬀerent organizational trajectories (Foran and
Peterson, 1992).
In the mouse optic nerve, MMP-9 enzymatic activity
levels gradually increase from P3 to P11, with elevated
transcript levels in the optic nerve at P7 (Larsen et al.,
2006) and strong gelatinolytic activity at P9 (Oh et al., 1999),
a time period overlapping with the strong expression of
myelin basic protein (MBP; Oh et al., 1999). In contrast,
in the rodent corpus callosum, MMP-9 protein expression
increases from P7 to P28 (Uhm et al., 1998), a time that
corresponds to developmental myelination. MMP protein
and gelatinolytic activity are localized around the OL cell
body, along OL processes and, notably, at the advancing
tip of OL processes (Oh et al., 1999; Šišková et al., 2009),
implicating MMP-9 in the ﬁrst step of myelination, OL process
outgrowth.
Indeed, in mouse, human and bovine cultures of OLs,
(Oh et al., 1999) increased OL process formation following
activation of PKC is accompanied by MMP-9 secretion, likely
the proform of the enzyme, and inhibition of MMP-9 activity
reduces OL process outgrowth (Uhm et al., 1998). In MMP-9
KO mice, though the development of myelin formation in the
optic nerve is comparable to WT mice, adult OLs in culture
have impaired process outgrowth in response to PKC activation
and reduced spontaneous process formation (Oh et al., 1999).
In the corpus collosum of MMP-9 KO mice, however, there
was a transient reduction in the amount of MBP from P7
to P10 and a decrease in the number of mature OL cells
(Larsen et al., 2006). The reduction in the number of mature
OL cells indicates a role for MMP-9 not only in process
extension but also in OL maturation. Šišková et al. (2009) further
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demonstrated that the interaction of MMP-9 with ECMmolecule
ﬁbronectin aﬀects the distribution of MMP-9 enzymatic activity
along OL processes, restricting its activity to OL cell bodies.
This change in MMP-9 localization from control conditions is
associated with the inhibition of OL diﬀerentiation, characterized
by fewer primary and secondary processes, implicating MMP-
9 enzymatic activity in OL diﬀerentiation (Šišková et al.,
2009).
Matrix metalloproteinase-9 may also be involved in the
second stage of myelination, ensheathment, through indirect
interactions with IGF-1. IGF-1 promotes OL proliferation
and/or survival, stimulates myelination production and increases
myelin thickness, and can be inhibited by IGFBP-6 (Ye
et al., 1995a). MMP-9 and MMP-12 can both cleave IGFBP-
6, while MMP-9 null mice show increased levels of IGFBP-
6 (Larsen et al., 2006) and application of IGF-1 increases
the number of mature OLs in MMP-12 null mice (Larsen
et al., 2006). These studies suggest a role for MMP-9 and
MMP-12 in cleavage of IGFBP-6 that disinhibits IGF-1 and
thereby promotes OL maturation and ensheathment. MMP
activity is further implicated in mediating contact between OL
cells and axons through a cleavage of the OL-speciﬁc 155-
kDa isoform of NF155, a member of the L1-family of cell
adhesion molecules (L1-CAM; Maier et al., 2006). This function
is important because the extracellular domain of NF155, localized
on the oligodendrocyte, can interact directly with adhesion
molecules located on the axonal membrane, such as contactin
(Maier et al., 2006). This suggests a role for MMP-mediated
cleavage of NF155 in establishing the interactions between
myelin and axons. Thus, MMP-9 is involved in multiple steps
of the myelination process including OL maturation, process
outgrowth and ensheathment of axons through its association
with ECM and neuronal receptors to ‘guide’ the myelination
process.
MMP-9 in Pathophysiology of Neurologic
Disorders
While the regulation of MMP-9 is important for many aspects
of normal CNS development and plasticity, misregulation
of MMP-9 levels and activity is increasingly implicated in
neurodevelopmental and psychiatric disorders that are associated
with aberrant brain development.
Fragile X Syndrome and Other Developmental
Disorders
Recently, MMP-9 has been implicated in several psychiatric
disorders that are associated with abnormal development
including FXS, autism spectrum disorder (ASD), bipolar disorder
and schizophrenia. Increased levels of MMP-9 have been
demonstrated in human subjects with FXS (Dziembowska et al.,
2013; Sidhu et al., 2014), ASD (Abdallah et al., 2012), bi-
polar disorder (Rybakowski et al., 2013) and treatment-resistant
schizophrenia (Yamamori et al., 2013). Still, there is limited
literature on the precise function of MMP-9 in these disorders.
Whether MMP-9 is responsible for the behavioral deﬁcits
associated with these disorders, or is a result of abnormal changes
in the brain is still unclear and requires further investigation.
However, recent research suggests that enhanced MMP-9 activity
is a major factor contributing to the pathophysiology of FXS and
epilepsy.
Fragile X syndrome is a trinucleotide repeat disorder that
leads to the transcriptional silencing of Fmr1. The FMR protein
encoded by the gene is involved in translation regulation,
and genetic deletion of the Fmr1 gene in mice mimics FXS-
associated deﬁcits, providing a useful model to study FXS.
The loss of translational suppression of MMP-9 by FMRP may
be driving some of the deﬁcits associated with FXS, such as
abnormal dendritic spine development and synaptic plasticity.
MMP-9 protein and enzymatic activity levels are increased in
the hippocampus of developing (P7), adolescent, and adult
Fmr1 KO mice (Bilousova et al., 2009; Janusz et al., 2013;
Gkogkas et al., 2014; Sidhu et al., 2014). This enhanced MMP-
9 activity contributes to abnormal PI3K-Akt-mTOR signaling
in the Fmr1 KO mouse, a pathway implicated in FXS and
other ASDs (Sidhu et al., 2014). Moreover, the ability of a
tetracycline derivative, minocycline, to inhibit MMP-9 activity
is suggested to underlie its beneﬁcial eﬀects in Fmr1 KO mice.
Minocycline treatment lowers MMP-9, but not MMP-2 levels,
and restores normal dendritic spine development in young Fmr1
KO mice (Bilousova et al., 2009), reduces audiogenic seizure
severity and rescues abnormal behaviors in both young and adult
Fmr1 KO mice (Rotschafer et al., 2012; Dansie et al., 2013).
Genetic deletion of MMP-9 also repairs abnormal dendritic
spine development, normalizes mGluR5-dependent LTD and
alleviates abnormal social behaviors and anxiety in Fmr1 KO
mice (Sidhu et al., 2014). In drosophila there are only two
MMPs, the secreted form MMP-1 and the membrane-anchored
form MMP-2. Inhibition of MMP-1 activity in dfmr1 null ﬂies,
a drosophila model of FXS, rescues some or all of the defects
associated with the deletion of dfmr (Siller and Broadie, 2011;
reviewed by Siller and Broadie, 2012). This was demonstrated
using three diﬀerent approaches: either (1) the overexpression of
tissue inhibitor of MMP (TIMP), (2) the generation of double
null mutants dfmr1;mmp1, or (3) treatment with minocycline
(Siller and Broadie, 2011; reviewed by Siller and Broadie,
2012).
In humans with FXS the levels of total MMP-9 enzymatic
activity are elevated in the plasma, without changes in MMP-2
levels (Dziembowska et al., 2013). The analysis of postmortem
FXS brain tissue samples also indicate elevated levels of MMP-
9 protein in both the hippocampus and neocortex (Gkogkas
et al., 2014; Sidhu et al., 2014). Minocycline treatment reduces
plasma levels of MMP-9 in most but not all subjects, and is
associated with improvements in behavior (Paribello et al., 2010;
Utari et al., 2010; Dziembowska et al., 2013; Leigh et al., 2013)
and a reversal of habituation deﬁcits in auditory event related
potentials (Schneider et al., 2013). This suggests that MMP-
9 suppression may be a useful therapeutic approach. Together
these studies indicate that increased MMP-9 levels in FXS may
underlie molecular, cellular and behavioral deﬁcits, many of
which are associated with abnormal plasticity, learning and
memory in FXS.
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MMP-9 in Epilepsy
The role of MMP-9 in epilepsy has been seen in both humans
(Suenaga et al., 2008; Konopka et al., 2013) and in animals, and
is a useful model of MMP-9 in aberrant plasticity. Epilepsy is a
disorder in which seizures become spontaneous and recurrent,
with highly synchronized activity. Aberrant neuronal plasticity
as a result of seizure activity or brain injury is thought to
underlie the progression of epilepsy. In both animal models of
epilepsy and human epilepsy subjects (Proper et al., 2000) this
aberrant plasticity can include neuronal loss in hippocampal
regions, astrogliosis, aberrant pruning of DG spines (Wilczynski
et al., 2008), reorganization of interneuron terminals (Pollock
et al., 2014), loss and/or disorganized PNN structures (McRae
et al., 2012; Pollock et al., 2014), and the sprouting of
mossy ﬁbers to create a recurrent network (Wilczynski et al.,
2008).
In young and adult human epilepsy patients MMP-9 protein
levels are higher compared to controls (Konopka et al., 2013).
Though other MMPs are increased as well, including MMP-2,
MMP-3 and TIMP-2 in adults, MMP-9 has the most prominent
and consistent increase in protein levels across ages (Konopka
et al., 2013). This protein expression is localized to neurons,
astrocytic processes and synapses, and is more strongly expressed
in dysmorphic neurons than healthy neurons (Konopka et al.,
2013). One mechanism thought to underlie epilepsy progression
may be through a change in the ratio of MMP-9 to TIMP-1, the
endogenous inhibitor of MMP-9. Subjects with varying forms of
epilepsy have an increase in the MMP-9/TIMP-1 ratio suggesting
an increase in the extracellular levels of MMP-9 activity (Suenaga
et al., 2008).
In rodent models of epilepsy, a kindling procedure can be used
where animals are electrically or chemically stimulated at sub-
threshold seizure levels over a period of weeks until spontaneous
seizures take place. MMP-9 KO mice require a longer kindling
period to develop epilepsy over controls (Wilczynski et al., 2008;
Mizoguchi et al., 2011), and experience less severe seizures
once fully kindled and an increased survival rate (Wilczynski
et al., 2008). Conversely, transgenic MMP-9 overexpressing rats
show increased susceptibility to epileptogenesis with kindling
(Wilczynski et al., 2008). After epilepsy induction in mice, overall
MMP-9 protein levels did not change in the DG; however, there
was a marked increase in the number of spines expressing MMP-
9 protein and in gelatinolytic activity localized to dendrites
(Wilczynski et al., 2008). Interestingly, DG spine density was
signiﬁcantly decreased in WT but not MMP-9 KO mice after
kainite-induced seizure indicating MMP-9may play a destructive
role promoting kainate-evoked spine pruning (Wilczynski et al.,
2008). The inhibition of MMP-9 in slices after kainate application
produces a 90% decrease in the density of mossy ﬁber sprouting
in the DG (Wilczynski et al., 2008). This indicates a functional
role for MMP-9 both in synaptic pruning and in mossy ﬁber
sprouting in rodent models of epilepsy.
It is likely that there are multiple targets of MMP-9 which
contribute to the progression of epilepsy. It is possible that MMP-
9 acts by creating a permissive state through cleavage of ECM
molecules, in particular, through cleavage of aggrecan. After
seizure induction there is a loss of PNNs around parvalbumin
positive interneurons (Pollock et al., 2014), including a speciﬁc
reduction in aggrecan and an increase in unbound hyaluronan
(McRae et al., 2012). Doxycycline hyclate, an antibiotic that
inhibits MMP-9, prevents the loss of PNNs after kindling and
delays epilepsy onset, possibly through the inhibition of MMP-
9 (Pollock et al., 2014). MMP-9 mediated cleavage of ECM may
also aﬀect neuronal activity and potentiate NMDAR currents
through the activation of integrins (see Synapse Development
and Plasticity for details). In addition, MMP-9 cleavage of pro-
BDNF into mature BDNF may play a role in the development
of epilepsy through mossy ﬁber sprouting. The BDNF to pro-
BDNF ratio increases in kindled WT mice, but not in MMP-9
KO mice, during the progression of epilepsy (Mizoguchi et al.,
2011) implicating MMP-9 in pro-BDNF cleavage. Because there
is no diﬀerence in overall BDNF levels in fully kindled mice, this
suggests that MMP-9 cleavage of pro-BDNF may accelerate the
onset of epilepsy (Mizoguchi et al., 2011).
Therapeutic Approaches
There are several drugs on the market that can directly or
indirectly alter MMP-9 levels and activity, some of which are
already in use in humans. For example, diazepam, a drug used
to treat epilepsy in humans, is able to suppress the development
of epilepsy in kindled mice and reduce MMP-9 levels (Mizoguchi
et al., 2011). Likewise both doxycycline (Pollock et al., 2014)
and minocycline (Beheshti Nasr et al., 2013; Dansie et al., 2013)
treatment can reduce seizure severity or epilepsy onset in mice.
Minocycline treatment also rescues behavioral, anatomical and
social deﬁcits in young and adult Fmr1 KOmice (Bilousova et al.,
2009; Rotschafer et al., 2012; Dansie et al., 2013). Clinical trials
on the eﬀects of minocycline in human subjects with FXS have
demonstrated improvement in language, social communication,
anxiety and attention (Utari et al., 2010) stereotypy, irritability
and hyperactivity (Paribello et al., 2010) as well as on behavioral-
improvement scales based on caregiver reports in a randomized
double-blind, placebo-controlled trial in children and adolescents
with FXS (Dziembowska et al., 2013; Leigh et al., 2013). What’s
more, electrophysiological measures in the auditory cortex of
human subjects with FXS indicate a reduction in auditory
hyper-reactivity with minocycline treatment (Schneider et al.,
2013).
Considering the widespread action of minocycline in the CNS,
the eﬀects of minocycline in FXS may not be limited to the
inhibition of MMP-9. Minocycline can inhibit other MMPs and
is shown to have anti-inﬂammatory and anti-apoptotic eﬀects
(reviewed by Elewa et al., 2006), can phosphorylate AMPA
receptors (Imbesi et al., 2008), and aﬀect MAPK signaling
(Nikodemova et al., 2006). Doxycycline similarly has various
eﬀects on CNS functions. On the other hand, MMP-9 is itself
expressed by many types of tissue throughout the body and,
as in the CNS, it can have both detrimental and beneﬁcial
eﬀects on biological systems (reviewed by Fingleton, 2008).
The potential side eﬀects of non-speciﬁc MMP-9 inhibition to
treat neurodevelopmental disorders have not been thoroughly
investigated, though MMP-9 KO mice have shown detrimental
side eﬀects as well as beneﬁts in animal models of cancer
(Coussens et al., 2000) and kidney disease (Zeisberg et al., 2006)
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and highlight the need for treatments speciﬁc to both the CNS
and to key points in the progression of a disorder. Nonetheless
recent studies discussed herein do demonstrate a relationship
between the ability of minocycline to inhibit MMP-9 in FXS
and a concomitant improvement on behavioral, morphologic
and physiological levels. Side eﬀects of the treatment as reported
in these studies are minor and are commonly associated with
gastrointestinal discomfort (Paribello et al., 2010; Utari et al.,
2010; Dziembowska et al., 2013). Altogether, this body of research
points to the need for additional studies to understand the
speciﬁc role of MMP-9 in the etiology of a disorder, including
the time frame during which MMP-9 activity may have the
largest deleterious eﬀects, and to develop treatments targeted
to MMP-9 in the progression of each disorder to further
improve the lives of people with intellectual disabilities and
autism.
Conclusion
Untangling the precise functions of MMP-9 is challenging. This
is due to the fact that it is expressed by both neurons and
glia; that its secretion and activation are regulated by a wide
variety of factors; and that it can act on multiple targets, each
of which can have diﬀerential and even opposing eﬀects. In this
review, we summarized the various roles of MMP-9 during early
postnatal development within the CNS, with a focus on sensory
development.
These developmental events, many of which recruit MMP-9
activity, occur in an organized and interactive fashion through
speciﬁc cellular targets and in response to sensory experience that
drives neuronal activity. MMP-9 recruited to speciﬁc extracellular
sites can cleave ECM creating room within the extracellular
space for cells to migrate and for neuronal processes to grow.
Yet beyond being simply permissive, MMP-9, through cleavage
and/or activation of cell surface and cell adhesion molecules, is
implicated in active dendritic spine remodeling and stabilization;
pre- and postsynaptic receptor dynamics; consolidation of LTP;
myelination and synaptic pruning. It is further implicated in
axonal sprouting, path ﬁnding, regeneration and degeneration.
MMP-9 is expressed just prior to and during CPP, a peak of
reorganization in the sensory cortex, and its activity is down
regulated in the adult brain. However, unregulated activity of
MMP-9 can have detrimental eﬀects on brain functions and
may underlie deﬁcits observed in several neurodevelopmental
disorders. It is therefore important to better understand
the mechanisms by which MMP-9 mediates early postnatal
development and its role in neurodevelopmental disorders.
Several key questions remain unanswered. The role of MMP-9
in auditory CPP, for instance, is yet to be studied. Tonotopic maps
in rodent primary auditory cortex do undergo reorganization
during a ‘sensitive window’ after which the network is less plastic.
Reorganization of the tonotopic frequency map can take place
with as few as 3 days exposure to a single tone, from P11 to
P13 (de Villers-Sidani et al., 2007), though time windows used to
test auditory CPP vary (Webster, 1983; Zhang et al., 2002; Barkat
et al., 2011; Kim et al., 2013). Recent studies have demonstrated
an auditory CPP deﬁcit in Fmr1 KO mice (Kim et al., 2013) that
may be related to enhanced levels of MMP-9 activity in the brain.
The role of MMP-9 in these auditory deﬁcits remains unclear.
Because clariﬁcation may lead to new therapeutic strategies to
treat auditory hypersensitivity and habituation deﬁcits seen in
FXS and ASD, understating this role is important.
Though MMP-9 seems to consistently be associated with
early postnatal development across many sensory regions and is
downregulated by adolescence and into adulthood, mechanistic
studies of MMP-9 have largely focused on l-LTP and synaptic
plasticity in cultured hippocampal neurons. Furthermore, it
is known that during development many receptors undergo
changes in sub-receptor composition, localization and/or
distribution within a network, as well as in their physiological
properties. Similarly, intracellular signaling molecules, as well as
cell surface and cell adhesion molecules and ECM components
all have altered expression throughout development. Therefore
it is uncertain whether the mechanisms underlying MMP-9
recruitment and activity in adolescent and adult hippocampal
neurons are conserved across cortical regions throughout
development.
In addition, given the overexpression of MMP-9 in multiple
neurodevelopmental disorders, it is important to understand
whether MMP-9 plays a regulatory and/or permissive role in
critical period development, speciﬁcally through its interactions
with ECM. The formation of PNN structures in the CNS, a
speciﬁc sub-type of ECM, has been linked to the closure of visual
CPP in rodents (reviewed by Hensch, 2005), associated with
developmental song learning in the zebra ﬁnch (Balmer et al.,
2009), and has been shown to be altered with sensory deprivation
in rodent barrel cortex (McRae et al., 2007). MMP-9 can directly
or indirectly induce cleavage of multiple components of PNN
structures, including laminin, brevican, tenascin-R, and aggrecan
(reviewed by Ethell and Ethell, 2007). Therefore elevated levels
of MMP-9 during development may induce aberrant cleavage
and alterations in PNN structures. It remains to be seen whether
PNNs are indeed altered in neurodevelopmental disorders and
whether MMP-9 inhibition can recover normal CPP through the
stabilization of PNNs.
While MMP-9 activity is important for normal CNS
development and for the consolidation of long-term memories
from development through adulthood, misregulated expression
and/or activity of MMP-9 is associated with many neurological
disorders. Therefore, understanding the action of MMP-9
within speciﬁc cortical regions, developmental periods and in
speciﬁc cellular processes is important for providing groundwork
for new therapies that target MMP-9 in treatments for
neurodevelopmental and other disorders.
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